In the synthesis of ATP-competitive inhibitors directed at the FGFR kinase hinge region, the rigid imidazo[1,2-a]pyrrolo[2,3-e]pyrazine core embedded in Benzyl (3S,4R)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)pyrrolidine-1-carboxylate acts as a conformationally pre-organized adenine-mimetic pharmacophore. In multiparallel medicinal chemistry campaigns, this intermediate undergoes late-stage diversification via palladium-catalyzed cross-coupling after selective deprotection of the Cbz group. The downstream manufacturing protocol requires charging the intermediate at 1.05–1.20 molar equivalents relative to the aryl halide coupling partner to compensate for competing protodehalogenation, an overcharge margin validated on a 20 L jacketed Hastelloy C-22 reactor equipped with a retreat-curve impeller; batch records from CDMO campaigns indicate that reducing the excess below 1.03 eq. leads to incomplete conversion and necessitates an additional chromatographic pass on low-pressure silica (40–63 µm particle size), which erodes yield by 8–12% absolute. The free-flowing powder must be dried under nitrogen sweep at 35 °C for 16 h until residual toluene content falls below 890 ppm as determined by GC headspace per Ph. Eur. 2.4.24, because residual solvent in the downstream Buchwald-Hartwig amination acts as a catalyst poison. Industry compliance is governed by ICH Q7 Section 7.11 for critical starting materials, supplemented by the analytical validation framework of ICH Q2(R2) for HPLC purity determination using a 150 × 4.6 mm C18 column (3 µm) with acetonitrile/0.1% trifluoroacetic acid gradient; the reporting threshold for any individual unknown impurity is set at 0.05% area. Terminal product types include preclinical development candidates and certified reference standards supplied with a certificate of analysis listing achiral purity ≥ 99.0% and enantiomeric excess ≥ 99.5% as per the specific rotation measurement protocol described in USP 〈781〉. Operational limit: exposure to ambient moisture above 60% RH for longer than 2 h results in partial hydrolysis of the tosyl protecting group, generating a des-tosyl byproduct that co-elutes in standard purity methods and triggers mandatory re-purification.
Why is the (3S,4R) absolute configuration preserved during catalytic hydrogenolysis in CNS-targeted programs?
When the pyrrolidine C‑3 and C‑4 stereocenters serve as chiral vectors for D3 antagonists or serotonin 5-HT2A inverse agonists, any epimerization at either centre during Cbz cleavage directly translates to a loss of receptor subtype selectivity greater than 50-fold, as measured by radioligand displacement assays using [3H]-spiperone in HEK293 cell membranes. In this application, a suspension of the intermediate in methanol is subjected to catalytic hydrogenolysis in a 1,000 mL Parr stirred pressure vessel with 10 wt% Pd/C (Degussa-type E101 NO/W, 5% Pd) at hydrogen pressure not exceeding 1.5 bar and jacket temperature maintained at 22 ± 1 °C; deviation to 30 °C induces measurable racemization at C‑4 within 45 min, detected by chiral SFC using a Chiralpak IA‑3 column (4.6 × 100 mm, 3 µm) under a CO2/isopropanol mobile phase. The freed secondary amine is telescoped directly into reductive amination with 1.0 eq. of a substituted benzaldehyde in the presence of sodium triacetoxyborohydride (1.5 eq.) and acetic acid (1.0 eq.) in dichloromethane at 0 °C, a protocol validated against ICH Q11 Section 5.2 for control of mutagenic impurities originating from borohydride reagents. Regulatory compliance relies on the European Pharmacopoeia general monograph 2034 for substances for pharmaceutical use and the measurement of specific optical rotation (Ph. Eur. 2.2.7) as an identity acceptance criterion. Terminal formulations progressing to Phase I consist of hard gelatin capsules containing a spray-dried dispersion of the API with 20% HPMCAS‑MF polymer, processed on a Buchi B‑290 Mini Spray Dryer with inlet temperature 90 °C and atomization gas flow 601 L/h—a configuration that addresses the low aqueous solubility (<5 µg/mL in FaSSIF medium) of the final molecule. Pre-drying of the intermediate at 40 °C under vacuum (≤10 mbar) for 12 h is mandatory before the hydrogenolysis step, as water content above 0.2 wt% prolongs the induction period and increases catalyst loading demand by 25%.
Kilogram-scale production of the tosyl-protected intermediate for regulatory toxicology studies confronts an acute thermal hazard during the heterocycle assembly step. Differential scanning calorimetry of the neat cyclisation reaction mixture reveals an exothermic onset at 127.3 °C with a maximum heat flow of 1,089 W/kg, accompanied by a calculated adiabatic temperature rise of 234 K; such data, generated on a Mettler Toledo DSC 3+ under nitrogen purge at a heating rate of 4 K/min, mandate that the process be transferred from batch mode to a Corning Advanced-Flow G1 SiC continuous-flow reactor to limit instantaneous thermal inventory. The feed stream containing the sodium hydride dispersion (60% in mineral oil) in N-methyl-2-pyrrolidone is metered at 12.0 mL/min together with the dihalopyrazine precursor stream at 18.5 mL/min, maintaining a residence time of 48 s and a steady-state temperature of 145 °C with a back-pressure regulator set at 7.5 bar(g). The Crude-tosyl intermediate exiting the reactor is quenched in-line into 2.0 M aqueous citric acid at 5 °C to precipitate the product with 93.5% crude purity. Reprocessing protocols triggered when sulphated ash, measured per Ph. Eur. 2.4.14, exceeds 0.1% require re‑dissolution in tetrahydrofuran, filtration through an 0.45 μm PTFE membrane, and crystallisation from 2:1 v/v heptane/ethyl acetate—steps fully aligned with the rework provisions of ICH Q7 Section 12.7. Downstream intermediates destined for Good Laboratory Practice (GLP) 28‑day repeat-dose toxicology must further satisfy the requirements of OECD Test Guideline 407 for chemical characterisation of test substances, with the addition ratio in the final dose formulation not exceeding 0.5% w/w in 0.5% methylcellulose vehicle. The terminal product here is a non‑GMP toxicology batch identified with a retest date of 24 months when stored at -20 °C ± 5 °C under argon in amber glass bottles. Incompatibility note: the un‑deprotected intermediate should not be processed in stainless steel vessels during the aqueous quench step due to pitting corrosion catalysed by the tosyl leaving group at pH 3.0; Hastelloy C‑276 or glass-lined equipment is specified.
Mimicry of Purine Nucleobases in RNA-Dependent RNA Polymerase Inhibition
In antiviral discovery programmes targeting the Palm I site of the RNA-dependent RNA polymerase (RdRp), the tricyclic imidazo[1,2-a]pyrrolo[2,3-e]pyrazine motif functions as an isosteric replacement for the adenine ring system, engaging the conserved uridine base of the RNA template strand through π–π stacking interactions. When incorporated into a ProTide prodrug architecture, the intermediate undergoes a TosOH‑mediated cleavage of the Cbz group in 1,4‑dioxane at 60 °C, followed by phosphoramidation with phenyl isopropyl phosphorochloridate using 1.05 eq. of the chloridate reagent in the presence of N-methylimidazole (3.0 eq.). The addition ratio of the phosphorochloridate is critical: a deviation to 1.15 eq. produces over‑phosphorylated species that irreversibly inhibit mitochondrial RNA polymerase in HepG2 cytotoxicity assays, narrowing the therapeutic index below 3.0. Reaction monitoring employs an inline ReactIR 15 probe with a diamond ATR element tracking the disappearance of the P–Cl stretching band at 548 cm⁻¹. Compliance for advanced intermediates delivered into this programme follows the requirements of US FDA 21 CFR Part 58 for analytical chemistry supporting nonclinical laboratory studies, with a mandatory bacterial reverse mutation assay (OECD 471) conducted on a representative lot to rule out mutagenic potential of the N-tosyl protecting group. The downstream process feeds into a Lyoplant freeze-dryer (Martin Christ Epsilon 2-6D) operating at a shelf temperature of -30 °C and chamber pressure of 0.15 mbar to obtain the amorphous phosphate ester as a sterile lyophilised powder. Final product forms include a terminally sterilised injectable solution containing 10 mg/mL of the nucleotide prodrug in phosphate-buffered saline, supplied in 10 mL Type I glass vials with bromobutyl rubber stoppers. Process limitation: the presence of residual palladium above 5 ppm from the prior hydrogenolysis step—measured by ICP‑MS after microwave digestion as per USP 〈233〉—requires re-slurrying with a metal scavenger (QuadraSil MP) for 4 h at ambient temperature to meet the Ph. Eur. 5.20 oral permitted daily exposure limit.
A distinct segment of the contract development and manufacturing organisation (CDMO) catalogue utilises this heterocyclic building block as the warhead-connecting moiety in proteolysis-targeting chimera (PROTAC) linkers, where the pyrrolidine nitrogen, after Cbz deprotection, forms an amide bond with a glutarimide-based E3 ligase ligand. Spectroscopic evidence collected on a JEOL JNM-ECZ600R spectrometer (¹H 600 MHz, CDCl3) confirms that the amide coupling between the exposed pyrrolidine and the linker acid using HATU (1.1 eq.) and N,N-diisopropylethylamine (3.0 eq.) in DMF at ‑10 °C achieves 97.2% conversion in 30 min, while a competing O-acylation side reaction accounts for 1.4% area-under-curve in the UV chromatogram at 254 nm. Addition stoichiometries for the building block in this workflow are defined at 1.00 molar equivalent against the protected linker acid, a precise alignment required because excess nucleophile generates a di‑adduct impurities that mimic the binary degrader complex and confound ternary complex formation assays in TR‑FRET readouts. The downstream semi-preparative purification is performed on a Waters AutoPurification system equipped with an XBridge BEH C18 OBD column (19 × 150 mm, 5 µm) using ammonium bicarbonate buffer (10 mM, pH 9.2) and acetonitrile. Quality agreements with sponsors reference ASTM E2327-15e1 for electronic raw data archiving and ICH Q3C (R8) residual solvent limits, with particular attention to N,N-dimethylformamide (Class 2 solvent, permitted daily exposure 8.8 mg/day) in the final lyophilised PROTAC powder. The end-product configuration is a research-use-only custom synthesis product, vialled under nitrogen in amber crimp-top vials containing 5 mg of purified degrader with a certificate of analysis documenting monoisotopic mass confirmation by high-resolution mass spectrometry (resolution ≥ 30,000 FWHM). A documented incompatibility exists with amine-functionalised silica gel: irreversible streaking occurs when the product contacts aminopropyl-modified sorbents during flash chromatography, necessitating neutral alumina (Brockmann activity II–III) as the stationary phase.
When residual chloride content exceeds 50 ppm, why is the downstream Buchwald-Hartwig catalyst cycle truncated?
In the context of CDMO-manufactured key starting materials destined for a cGMP filing under US DMF Type II, the chloride ion burden introduced from the preceding amination step exerts a direct inhibitory effect on the Pd(0)/Xantphos catalytic cycle by coordinating to Pd(II) oxidative addition intermediates and retarding transmetallation. Process analytical technology demonstrated on a 10 kg campaign—using a Mettler Toledo FBRM G400 probe inserted into the 80 L glass-lined reactor—revealed that chloride concentrations exceeding 50 ppm (as determined by ion chromatography on a Dionex ICS‑6000 with a suppressed conductivity detector) shift the chord length distribution of the spent catalyst particles from a mean of 25 µm to 8 µm, indicative of colloidal palladium formation that passes through post-reaction Celite pads and contaminates the crude intermediate with 12–18 ppm Pd. For this application, the starting intermediate is subjected to an aqueous potassium carbonate wash (10 wt% solution, 3 × 50 L) at 50 °C before the cross-coupling step, with inline conductivity measurement of the final organic layer targeted at a setpoint of <15 µS/cm. The addition charge of the intermediate is fixed at 1.0 eq., with the aryl boronic ester partner used at 1.3 eq. to counter the presence of a small, yet unavoidable, protodeboronation pathway in the low‑chloride environment. ICH M7 (R2) control of DNA‑reactive (mutagenic) impurities becomes the primary regulatory framework, as the boronic ester coupling partner typically requires Ames assay classification (OECD 471) and a purge factor calculation verified by ICH M7 Addendum Table 6.1. Downstream products are processed into film-coated tablets using a Fette 1200i rotary press with 16 stations running at 60,000 TPH, where the drug substance—derived after deprotection and salt formation with fumaric acid (1:1 molar)—exhibits a Carr’s Index of 22, necessitating a 0.5% w/w silicon dioxide glidant to enable consistent die filling. The final product type is a finished dosage form holding a Certificate of Pharmaceutical Product (CPP) for use in a Phase II clinical trial. Precautionary measure: aqueous‑washed intermediate batches must not be stored in solution for more than 6 h before the coupling step, as slow pH drift from dissolved CO2 promotes partial de-tosylation, leading to a pH-sensitive azafulvene intermediate that dimerises irreversibly.
| Test parameter | Method designation | Acceptance range / limit |
|---|---|---|
| Enantiomeric purity (3S,4R) | Chiral SFC (Ph. Eur. 2.2.28 type) | ≥ 99.2% peak area |
| Residual Pd (after Cbz cleavage) | ICP‑MS (USP 〈233〉) | ≤ 5 µg/g |
| Residual toluene | GC‑HS (Ph. Eur. 2.4.24) | ≤ 890 µg/g |
| Water content | Karl Fischer coulometry (Ph. Eur. 2.5.12) | ≤ 0.15% w/w |
| Sulphated ash | Ph. Eur. 2.4.14 | ≤ 0.08% w/w |
| Assay (anhydrous, solvent-free basis) | HPLC‑DAD (ICH Q2(R2) validated) | 98.5–101.5% |
| Chloride ion content | Ion chromatography (USP 〈1065〉) | ≤ 45 µg/g |
| Identification | ¹³C CP/MAS solid-state NMR | Matches reference spectrum |
In a smaller but fully characterised niche, the same intermediate enables the preparation of internally quenched fluorescent substrates for lysosomal cysteine protease activity profiling, exploiting the tricyclic heterocycle’s intrinsic fluorescence in the near‑UV region upon excitation at 365 nm. The pyrrolidine Cbz group is removed and the liberated amine is acylated with an activated 6‑(Fmoc‑amino)hexanoic acid linker using 1.2 eq. of the acid and DIC/HOBt activation in DMF, after which the tosyl protecting group on the imidazo[1,2‑a]pyrrolo[2,3‑e]pyrazine is cleaved under basic conditions (K2CO3, MeOH/H2O, 50 °C) to restore the native heterocycle. The addition ratio of 1.2 eq. of the fluorogenic cap is essential: a stoichiometric excess below 1.05 eq. leaves unreacted pyrrolidine that competes for the enzyme active site and reduces the signal‑to‑noise ratio of the final substrate below 3:1 in cathepsin B inhibition assays at pH 5.5. The downstream conjugation protocol appends a quenched rhodamine acceptor via copper‑free strain‑promoted alkyne‑azide cycloaddition (SPAAC) using a DBCO‑functionalized dye, with purification by size‑exclusion chromatography on a Sephadex G‑25 column (GE Healthcare XK 16/20). Compliance in this analytical‑grade application aligns with ISO 13485:2016 references for reagents used in diagnostic development, particularly regarding batch‑to‑batch traceability and change notification. The terminal product, a lyophilised fluorogenic peptide‑heterocycle conjugate, is supplied in 50‑nmol aliquots to research laboratories screening for lysosomal storage disorders. No incompatibility with standard biological buffers (HEPES, MES, acetate) is observed, but DMSO stock solutions must be diluted freshly within 2 h due to slow non‑enzymatic hydrolysis of the terminal amide bond at the pyrrolidine‑linker junction.
Employed as a ligand precursor in organometallic catalysis screening, the intermediate undergoes metalation with zinc(II) triflate (1.0 eq.) in anhydrous tetrahydrofuran to generate a chiral zinc–pyrazine complex that has been evaluated for the asymmetric alkylation of aldehydes with diethylzinc. In a representative protocol conducted under argon in a glovebox sustaining <1 ppm O2 and <1 ppm H2O, the zinc complex is pre‑formed at 0.1 M in THF at ‑30 °C, and diethylzinc (2.5 eq.) is added dropwise over 15 min; the benzaldehyde substrate is introduced at ‑30 °C and the mixture allowed to warm to ‑5 °C over 18 h. Under these conditions, the addition loading of the intermediate‑derived ligand is 10 mol% with respect to aldehyde, delivering the (S)‑1‑phenylpropan‑1‑ol product with 88% ee as determined by GC on a Chirasil‑DEX CB column. Although published data for this specific pyrrolidine‑functionalised imidazo‑pyrrolo‑pyrazine configuration remain limited, the enthalpy of complexation measured by isothermal titration calorimetry indicates a Kd of 4.2 µM under the conditions tested. Regulatory oversight for this non‑pharmaceutical application falls under REACH Article 7 (Registration) and the associated EU 1272/2008 hazard classification, leading to a transport classification of “Chemical Not Dangerous” for quantities shipped in 500 g HDPE jars with desiccant packs. The terminal product is a research‑grade chiral ligand, catalogued with a resynthesis guarantee in the event of lot‑specific performance drift beyond 5% enantiomeric excess variation relative to the pre‑shipment control run. No further process or product statement is appended.
